2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
The Hoosier state still has an armful of health challenges, from high levels of smoking and obesity to the prevalence of air pollution and cardiovascular disease.
The “toxic” office environment at a small St. Vincent Health office had broken out during an unprecedented wave of acquisitions of physician practices in central Indiana.
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
A new report by the Centers for Disease Control and Prevention is pushing states with high Medicaid smoking rates to do more to encourage enrollees to quit and live longer.
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
In the latest move by an Indiana utility to reduce its use of coal, the Evansville-based utility plans to build a solar farm and substantially increase the use of natural gas as a fuel source.
Analysts are all over the map on how investors should react to the Indianapolis-based drugmaker’s news that a promising drug failed to help patients.
Investors pummeled Eli Lilly and Co.’s stock Wednesday on the news that its experimental drug for Alzheimer’s disease failed to help patients, but a chorus of pharmaceutical analysts say they weren’t shocked by the setback.
David Stippler, Indiana’s official advocate for utility customers, who often pushes back against utilities that want to raise rates, plans to retire Jan. 1 after 11 years in office.
What happens to a laboratory glove after a doctor, nurse or lab worker snaps it off and throws it in the bin? Usually, it goes to a landfill, but Purdue and partners are working to change that.
Hospitals are under pressure to serve healthier fare. Patients, health groups and news organizations are turning up the fire.
For patients, the difference between getting an operation now or in January could amount to thousands of dollars out of pocket.
Fairbanks, an Indianapolis not-for-profit that focuses on treating alcohol and drug addiction, has changed its leadership again, just a year after bringing in a new executive from Ohio.
IU Health continues to pick up small hospitals around the state to help feed patients into its vast network.
Colette D. Jackson claims in a lawsuit that Eskenazi retaliated against her after she discovered the hospital was improperly billing the federal government and Indiana for potentially hundreds of patients whose bills were already being paid by research grants.